window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

mental health innovation

  • Clinical Trials,Digital Health,Mental health,Neurosciences

    Digital therapeutic cuts schizophrenia’s negative symptoms in trial

    Boehringer Ingelheim and Click Therapeutics have reported Phase 3 results [...]

    October 13, 2025
  • Drug Development,Market Access & Commercialization,Partnerships & Funding,Patient Centricity

    Could a psychedelic transform depression care? Cybin CEO on scaling CYB003 with Osmind deal

    Cybin’s lead psychedelic-based candidate CYB003, designed as an adjunctive treatment [...]

    June 25, 2025
  • Clinical Trials,Partnerships & Funding,Patient Centricity,Regulatory Affairs,Technology and platforms

    Cybin teams up with Osmind to advance Phase 3 psychedelic therapy for depression

    As psychedelic-assisted therapies move closer to mainstream psychiatric care, Cybin, [...]

    June 2, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top